(1)
Stockholm, February 11, 2020 - Nasdaq (Nasdaq: NDAQ) announces that trading in
Fractal Gaming Group AB s shares (short name FRACTL) commences today on Nasdaq
First North Premier Growth Market. The company belongs to the Technology sector
and is the 7th company to be admitted to trading on Nasdaq s Nordic markets in
2021.
Fractal is a leading company in the premium segment of PC gaming products. The
Company was founded in 2010 and its products are currently sold in more than 50
markets worldwide. Fractal is the market leader in premium PC cases in several
geographic markets, for example in the Nordic region, is top two in Japan, and
(2) DJ Media and Games Invest plc: Closing of the Acquisition of KingsIsle - KingsIsle Represents New Strike Zone Media and Games Invest plc: Closing of the Acquisition of KingsIsle - KingsIsle Represents New Strike Zone 08, February 2021 - Media and Games Invest plc (Frankfurt Stock Exchange: M8G), (Nasdaq First North Premier Growth Market: M8G) ( MGI or the Company ), has concluded the closing of the Share Purchase and Transfer Agreement with the owners of KingsIsle Entertainment Inc ( KingsIsle ) to acquire 100% of the shares of KingsIsle as planned. The transaction is adding the successful massive multiplayer games Wizard101 as well as Pirate101 to the MGI gaming portfolio, two games with very loyal user bases and long-term sustainable revenue streams.
Sweden-based Fractal Gaming Group AB, better known in PC DIY circles by the moniker Fractal Design, is planning to raise cash via a US Nasdaq IPO. Specifically, it intends to list shares in an IPO on the Nasdaq First North Premier Growth Market. Shares will come largely from existing shareholder Litorina IV, which appears to want to release its principal shareholder investment for other projects. Ahead of this IPO there was talk of Fractal looking to be bought out in its entirety, so it looks like it is now executing plan B.
Commonly an IPO would be good for a company s prospects by providing a platform where it can raise cash to further invest in R&D, market development, manufacturing facilities and so on. With the purpose of this IPO to seemingly to release Litorina IV s capital (it has held since 2016), there may be less of that good stuff for the company. However, a reluctant principal shareholder isn t a great asset either, so the change should be good.
Sweden-based Fractal Gaming Group AB, better known in PC DIY circles by the moniker Fractal Design, is planning to raise cash via a US Nasdaq IPO. Specifically, it intends to list shares in an IPO on the Nasdaq First North Premier Growth Market. Shares will come largely from existing shareholder Litorina IV, which appears to want to release its principal shareholder investment for other projects. Ahead of this IPO there was talk of Fractal looking to be bought out in its entirety, so it looks like it is now executing plan B.
Commonly an IPO would be good for a company s prospects by providing a platform where it can raise cash to further invest in R&D, market development, manufacturing facilities and so on. With the purpose of this IPO to seemingly to release Litorina IV s capital (it has held since 2016), there may be less of that good stuff for the company. However, a reluctant principal shareholder isn t a great asset either, so the change should be good.
Share this article
GOTHENBURG, Sweden, Jan. 15, 2021 /PRNewswire/
Isofol Medical AB (publ) ( Isofol ), (Nasdaq First North Premier Growth Market: ISOFOL) announces that a poster presentation is presented today at ASCO Gastrointestinal Cancers Symposium (ASCO-GI). The abstract present results from the Phase I/IIa ISO-CC-005 study which shows a correlation between clinical benefit and gene expression of the folate pathway in patients with metastatic colorectal cancer treated with 5-FU-based chemotherapy in combination with arfolitixorin. Furthermore, Isofol gives an update of the timing of the interim analysis in the global Phase III AGENT study.
In connection to ASCO-GI, Isofol together with QuartzBio, the Sahlgrenska Academy at University of Gothenburg and Sahlgrenska University Hospital, will present a poster with the title Folate pathway gene expression in metastatic colorectal cancer patients treated with arfolitixorin/5-FU-based chemotherapy on asco.org between 2.00 PM -